Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Highlights from ASCO 2019

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.19
Views: 5668
Rating:

Asst. Prof Bishal Gyawali and Monique Biryiana

Asst. Prof Bishal Gyawali and Monique Biryiana speak at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the highlights from this year's conference.

Asst. Prof Gyawali discusses several presentations that address topics ranging from racial disparities, accelerated drug approvals and the importance of assessing overall survival in clinical trials.

The presentations that he referred to are:

Affordable Care Act (ACA): Medicaid expansion impact on racial disparities in time to cancer treatment.
Phase III ANNOUNCE trial: A randomised, placebo-controlled, double-blind trial of doxorubicin olaratumab versus doxorubicin and placebo in patients with advanced soft tissue sarcomas.
Phase III MONALEESA-7 trial: In which Sara A. Hurvitz spoke with ecancer about the effect of endocrine therapy with or without ribociclib on overall survival in premenopausal patients.
Phase III POLO trial: In which Dr Hedy Kindler spoke with ecancer about the role of olaparib as a maintenance treatment following first-line, platinum-based chemotherapy in patients with a BRCA mutation and metastatic pancreatic cancer.
Phase III ENZAMET trial: In which Dr Christopher Sweeney spoke with ecancer about the effect of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer on overall survival.
Phase III TITAN trial: A double-blind, randomised study of apalutamide versus placebo in patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy.
Phase III KEYNOTE-062 trial: In which Dr Josep Tabernero spoke with ecancer about pembrolizumab with or without chemotherapy, compared to chemotherapy alone for gastric or gastroesophageal junction adenocarcinoma.

All opinions expressed in this video are the speakers own and do not reflect that of any institution.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation